EUVIMEDEUVIMED entdecken
Crossref

Outcomes With Percutaneous Debulking of Tricuspid Valve Endocarditis

Robert S Zhang iD, Usman Alam, Muhammad H Maqsood iD, Yuhe Xia iD, Rafael Harari, Norma Keller iD, Lindsay Elbaum, Sunil V Rao iD, Carlos L Alviar, Sripal Bangalore iD

Circulation: Cardiovascular Interventions · 2023-07 · 16 (7)

DOI: 10.1161/circinterventions.123.012991 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation: Cardiovascular Interventions, 2023-07. Verfasst von Robert S Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine (R.S.Z., R.H., N.K., L.E., S.V.R., C.L.A., S.B.), New York University. Hauptthemen laut MEDLINE: Heart Valve Prosthesis Implantation, Endocarditis, Endocarditis, Bacterial. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In patients with tricuspid valve infective endocarditis, percutaneous debulking is a treatment option. However, the outcomes of this approach are less well known. METHODS: We performed a retrospective analysis of all patients who underwent percutaneous vegetation debulking for tricuspid valve infective endocarditis from August 2020 to November 2022 at a large academic tertiary care public hospital. The primary efficacy outcome was procedural success defined by clearance of blood cultures. The primary safety outcome was any procedural complication. For the composite outcome of in-hospital mortality or heart block, outcomes were compared (sequential noninferiority and superiority) with published surgical outcomes data. RESULTS: Of the 29 patients with tricuspid valve infective endocarditis who underwent percutaneous debulking, the average age was 41.3±10.1 years, all patients had septic pulmonary emboli with 27 (93.1%) patients having cavitary lung lesions before the procedure. For the efficacy outcomes, 28 patients (96.6%) had clearance of cultures after their procedure, mean white blood cell count significantly decreased from 16.8±1.4×10 3 to 12.6±1.0×10 3 per µL ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Valve Prosthesis ImplantationEndocarditisEndocarditis, BacterialHumansAdultMiddle AgedTricuspid ValveRetrospective StudiesHospital MortalityCytoreduction Surgical ProceduresTreatment OutcomeHeart Block

Stichwörter der Autor:innen

body temperatureendocarditisfollow-up studieshospital mortalitylung

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine (R.S.Z., R.H., N.K., L.E., S.V.R., C.L.A., S.B.), New York University.
  • Department of Medicine (U.A.), New York University.
  • Department of Medicine, Lincoln Medical Center, Bronx, NY (M.H.M.).
  • Department of Population Health, New York University Grossman School of Medicine (Y.X.).

ORCID-Profile: Robert S Zhang, Muhammad H Maqsood, Yuhe Xia, Norma Keller, Sunil V Rao, Sripal Bangalore

Zitieren

APA

Zhang, R. S., Alam, U., Maqsood, M. H., Xia, Y., Harari, R., Keller, N., Elbaum, L., Rao, S. V., Alviar, C. L., & Bangalore, S. (2023). Outcomes With Percutaneous Debulking of Tricuspid Valve Endocarditis. Circulation: Cardiovascular Interventions, 16(7). https://doi.org/10.1161/circinterventions.123.012991

Vancouver

Zhang RS, Alam U, Maqsood MH, Xia Y, Harari R, Keller N, et al. Outcomes With Percutaneous Debulking of Tricuspid Valve Endocarditis. Circulation: Cardiovascular Interventions. 2023;16(7). doi:10.1161/circinterventions.123.012991

BibTeX
@article{Zhang2023,
  author = {Zhang, Robert S and Alam, Usman and Maqsood, Muhammad H and Xia, Yuhe and Harari, Rafael and Keller, Norma and Elbaum, Lindsay and Rao, Sunil V and Alviar, Carlos L and Bangalore, Sripal},
  title = {Outcomes With Percutaneous Debulking of Tricuspid Valve Endocarditis},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2023},
  volume = {16},
  number = {7},
  doi = {10.1161/circinterventions.123.012991}
}
Kostenlos starten →